Related Experiment Video
Updated: May 19, 2026
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
Development of terbinafine solid lipid nanoparticles as a topical delivery system
Ying-Chen Chen1, Der-Zen Liu, Jun-Jen Liu
1School of Pharmacy, College of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.
International Journal of Nanomedicine
|August 28, 2012
Summary
New solid lipid nanoparticles (SLNs) offer improved terbinafine (TB) delivery, potentially reducing treatment times. This antifungal innovation could simplify topical treatments for skin conditions.
Area of Science:
- Nanotechnology in Pharmaceutical Sciences
- Dermatological Drug Delivery Systems
- Antifungal Agent Formulation
Background:
- Conventional terbinafine (TB) treatments suffer from long durations and frequent application.
- Developing novel drug delivery systems is crucial to enhance antifungal efficacy and patient compliance.
- Solid lipid nanoparticles (SLNs) are promising for encapsulating lipophilic drugs like TB.
Purpose of the Study:
- To develop and characterize solid lipid nanoparticles (SLNs) for improved terbinafine (TB) delivery.
- To evaluate the skin penetration efficacy of TB-loaded SLNs compared to a commercial product.
- To address limitations of current terbinafine treatments regarding administration frequency and duration.
Main Methods:
- SLNs were formulated using a microemulsion technique with various lipid phases (GMS, Compritol® 888, Precirol® ATO 5), surfactants, and propylene glycol.
- Ternary phase diagrams were constructed to optimize SLN formulation.
- In vitro skin penetration studies using nude mouse skin were conducted to quantify TB levels in stratum corneum, epidermis, and dermis; particle size analysis confirmed stability.
Main Results:
- Optimal SLN formulations contained <5% lipid phase and >50% water phase.
- Increasing the lipid phase percentage enhanced TB skin penetration.
- The ACP1-GM1 formulation (4% lipid phase, Compritol® 888:GMS 1:1) showed comparable stratum corneum penetration to Lamisil® Once™ and higher dermal penetration at 12 hours.
Conclusions:
- The developed SLN formulation (ACP1-GM1) demonstrates potential for enhanced terbinafine (TB) delivery.
- A 12-hour application of ACP1-GM1 may offer efficacy comparable to 24-hour application of Lamisil® Once™.
- This SLN approach could significantly reduce terbinafine treatment duration and improve patient compliance.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...